Cisplatin-induced changes in calcitonin gene-related peptide or TNF-α release in rat dorsal root ganglia in vitro model of neurotoxicity are not reverted by rosiglitazone

• Published in: Neurotoxicology (Park Forest South) 2022-12, Vol.93, p.211-221
• Main Authors: Oliveira, Henrique Rodrigues, Coelho, Michella Soares, Neves, Francisco de Assis Rocha, Duarte, Djane Braz
• Format: Article
• Language: English
• Subjects: Animals; Calcitonin Gene-Related Peptide; CGRP; Cisplatin; Cisplatin - toxicity; Ganglia, Spinal; Hypoglycemic Agents - pharmacology; Neurotoxicity; Neurotoxicity Syndromes - drug therapy; PPAR; PPAR gamma - genetics; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Rosiglitazone - pharmacology; Thiazolidinediones - therapeutic use; Thiazolidinediones - toxicity; TNF-α; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 0161-813X; 1872-9711
• DOI: 10.1016/j.neuro.2022.10.002

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of anticancer drugs which affect the peripheral nervous system, as occurs with cisplatin treatment. Nowadays, one strategy in development to prevent, minimize and/or revert CIPN is neuroprotection. Therefore, we have evaluated the signaling pathways involved in CIPN and the effect of rosiglitazone, a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist. Dorsal Root Ganglia (DRG) were harvested from Wistar rats (Rattus norvegicus), the cells were dissociated, plated, and maintained with nerve growth factor for 9 days. On day 8, the cells were treated with cisplatin, rosiglitazone and/or T0070907 (PPAR-γ antagonist) for 24 h. The cell viability was measured by trypan blue exclusion method, the mRNA was quantified by real-time RT-PCRq and the release of TNF-α and calcitonin gene-related peptide (CGRP) was evaluated by ELISA. Cisplatin, rosiglitazone or T0070907 treatments did not decreased the cell viability on the primary DRG cultures cells. Cisplatin treatment induced a decrease of PPAR-γ and -β/δ mRNA, while the co-treatment with rosiglitazone inhibited this cisplatin-induced effect. Moreover, T0070907 did not change the observed results, indicating that the rosiglitazone’s effect could be due to mechanisms beyond PPAR-γ activation. Also, the rosiglitazone effect is not exclusively to DRG cells since there was an increase of PPAR-γ mRNA expression in 3T3-L1 cells. Furthermore, rosiglitazone did not modulate the cisplatin decrease neuronal function of DRG cells (TNF-α and CGRP release). Cisplatin decreased the gene expression of PPAR-γ and -β/δ, while the rosiglitazone treatment inhibited these effects via PPAR-γ independent pathway. Rosiglitazone did not show improvement in modulation of TNF-α or CGRP release impaired by cisplatin. •Cisplatin decreases the expression of Ppar-γ and -β/δ on CIPN in vitro model.•Rosiglitazone inhibits cisplatin-effects on gene expression on CIPN.•Cisplatin increases TNF-α and decrease the CGRP release on CIPN.•Rosiglitazone do not modulate the TNF-α and CGRP release impairment on CIPN.